CytomX Therapeutics (CTMX) Current Assets (2014 - 2026)

CytomX Therapeutics' Current Assets history runs 13 years deep, the most recent figure standing at $353.1 million for Q1 2026.

• Quarterly Current Assets rose 307.6% year-over-year to $353.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $353.1 million (up 307.6% YoY) and the FY2025 annual result came in at $143.9 million, up 34.12% from the prior year.
• Current Assets was $353.1 million for Q1 2026 at CytomX Therapeutics, up from $143.9 million in the prior quarter.
• Across five years, Current Assets topped out at $353.1 million in Q1 2026 and bottomed at $86.6 million in Q1 2025.
• A 5-year average of $186.0 million and a median of $182.9 million in 2023 frame the typical range for Current Assets.
• Annual changes were most pronounced in 2025 — Current Assets sank 48.2% — and 2026, when it surged 307.6%.
• CytomX Therapeutics' Current Assets stood at $237.1 million in 2022, then declined by 22.85% to $182.9 million in 2023, then tumbled by 41.34% to $107.3 million in 2024, then soared by 34.12% to $143.9 million in 2025, then jumped by 145.34% to $353.1 million in 2026.
• Business Quant data shows CTMX's Current Assets at $353.1 million in Q1 2026, $143.9 million in Q4 2025, and $149.2 million in Q3 2025.